<code id='AD5421E184'></code><style id='AD5421E184'></style>
    • <acronym id='AD5421E184'></acronym>
      <center id='AD5421E184'><center id='AD5421E184'><tfoot id='AD5421E184'></tfoot></center><abbr id='AD5421E184'><dir id='AD5421E184'><tfoot id='AD5421E184'></tfoot><noframes id='AD5421E184'>

    • <optgroup id='AD5421E184'><strike id='AD5421E184'><sup id='AD5421E184'></sup></strike><code id='AD5421E184'></code></optgroup>
        1. <b id='AD5421E184'><label id='AD5421E184'><select id='AD5421E184'><dt id='AD5421E184'><span id='AD5421E184'></span></dt></select></label></b><u id='AD5421E184'></u>
          <i id='AD5421E184'><strike id='AD5421E184'><tt id='AD5421E184'><pre id='AD5421E184'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:3181
          Silhouetted hands passing money. -- health business coverage from STAT
          Adobe

          The federal government has started penalizing Medicare Advantage insurers that have one common, glaring problem: Faulty technology systems are leading to people paying more for care and coverage than they should be.

          The Centers for Medicare and Medicaid Services fined three different Medicare Advantage plans this month, each one getting dinged differently for the way they overcharged their members. The fines are minuscule for the insurance companies — roughly equivalent to some pennies under a couch cushion — but they could serve as warnings for companies to clean up their compliance and IT infrastructure before regulators knock on their doors again.

          advertisement

          “Just the knowledge that CMS will be back one day and that you better have this fixed, I think, does have a sentinel effect,” said Philip Legendy, an attorney at Ballard Spahr who represents Medicare Advantage plans. “And if you’re doing it over and over, it could be viewed as intentional.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          The Readout: Amylyx, Alumis, and Lundbeck drug updates
          The Readout: Amylyx, Alumis, and Lundbeck drug updates

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Young boy dies in trial for Pfizer Duchenne gene therapy

          MarkLennihan/APAyoungboydiedinatrialforPfizer’sexperimentalgenetherapyforDuchennemusculardystrophy,t